{
    "Trade/Device Name(s)": [
        "ENVISION\u2122 Blood Glucose Test System",
        "ENVISION\u2122 Blood Glucose Testing System",
        "ENVISION\u2122 Monitor"
    ],
    "Submitter Information": "Infopia Co., Ltd.",
    "510(k) Number": "K082020",
    "Predicate Device Reference 510(k) Number(s)": [
        "K021819"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW",
        "CGA",
        "JJX"
    ],
    "Summary Letter Date": "November 20, 2008",
    "Summary Letter Received Date": "November 21, 2008",
    "Submission Date": "July 15, 2008",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ENVISION\u2122 Monitor"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemical detection",
        "Glucose oxidase reaction"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Test strip",
        "Monitor"
    ],
    "Document Summary": "FDA 510(k) summary for ENVISION\u2122 Blood Glucose Test System using electrochemical glucose oxidase detection for capillary whole blood glucose measurement",
    "Indications for Use Summary": "For quantitative measurement of glucose in capillary whole blood from multiple sites by diabetic patients or healthcare professionals as an aid in diabetes management; not for diagnosis or screening of diabetes or neonatal use",
    "fda_folder": "Clinical Chemistry"
}